CANSINOBIO (06185) announced that it has received a Supplemental Drug Application Approval Notice from the National Medical Products Administration (NMPA). According to the notice, the NMPA has approved the expansion of the applicable age range for the company's ACYW135 Group Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Carrier), marketed as Menhycyte™. The approved age group has been extended from "children aged 3 months to 3 years (47 months)" to "children aged 3 months to 6 years (83 months)."

Menhycyte™ is the first quadrivalent meningococcal conjugate vaccine developed in China. Its initial launch helped narrow the gap between China and developed countries in this field and addressed the previous lack of high-end vaccine options. This expanded indication provides an improved solution for the prevention of meningococcal disease in children aged 6 years and under in China. Leveraging its innovative advantages, Menhycyte™ has demonstrated strong market performance and achieved a continuously increasing market share.